Cannabidiol Decreases Metalloproteinase Activity and Normalizes Angiogenesis Factor Expression in UVB-Irradiated Keratinocytes from Psoriatic Patients

Spread the love


. 2021 Oct 13;2021:7624389.

doi: 10.1155/2021/7624389. eCollection 2021.

Affiliations

Item in Clipboard

Agnieszka Gęgotek et al. Oxid Med Cell Longev. .

Abstract

The development of psoriasis is associated with the consequences of oxidative stress and inflammation leading to metabolic changes locally, in the skin cells, and systemically, in the blood. Therefore, the aim of this study was to analyze the effect of psoriasis vulgaris (PsV) and psoriatic arthritis (PsA) on the basal plasma/keratinocyte levels of matrix metalloproteinases (MMPs), tissue inhibitors of matrix metalloproteinases (TIMPs), and angiogenesis factors, as well as to evaluate the effect of CBD on these parameters in keratinocytes isolated from psoriatic/healthy individuals with and without in vitro irradiation by UVB. A quantitative chemiluminescent method of detection based on an ELISA protocol and zymography technique was used during analysis. It was shown that activity levels of MMP-9 and TIMP-2 in PsA plasma were higher than in PsV. Changes in the proteolytic activity were accompanied by an increase in markers of angiogenesis (angiopoietin-2, HGF, VEGF, TNFα, PDGF, FGF), where in the specific case of angiopoietin-2 and TNFα, the overexpression in PsV was significantly stronger than in PsA. CBD application to keratinocytes partially restored levels of MMP-1/2/3/7 and TIMP-1/2 (in an effect which was particularly enhanced by UVB irradiation), as well as levels of the examined angiogenic factors except TNFα (levels of which were increased in psoriatic keratinocytes and decreased in healthy keratinocytes). Presented results indicate that CBD may be suggested as an antiangiogenic factor that reduces the proinflammatory action of UVB in psoriatic keratinocytes and partially has a protective effect for healthy keratinocytes.

Conflict of interest statement

The authors declare that there is no conflict of interest regarding the publication of this article.

Figures

Figure 1

Figure 1

The spot distribution in the Q-Plex™ Human MMP (a) and Q-Plex™ Human Angiogenesis (b) and the images of the obtained curves for targeted proteins (c, d).

Figure 2

Figure 2

The level of metalloproteinases (MMP-1, MMP-2, MMP-3, MMP-7, and MMP-9) and metalloproteinase inhibitors (TIMP-1/2) in plasma of patients with psoriasis vulgaris (PsV, n = 20) and psoriatic arthritis (PsA, n = 20) compared to plasma of healthy subjects (control group, n = 20). Mean values ± SD are presented; x statistically significant differences vs. control group, p < 0.05; y statistically significant differences vs. PsA group, p < 0.05.

Figure 3

Figure 3

The activity of metalloproteinases (MMP-2 and MMP-9) in plasma of patients with psoriasis vulgaris and psoriatic arthritis compared to plasma of healthy subjects (control group). Presented results are (a) image of gelatin zymography, (b) the intensity of the signals for individual lines, and (c) the average of data from each group.

Figure 4

Figure 4

The level of the growth factors and markers of angiogenesis (angiopoietin-2, HGF, PDGF, TNFα, IL-8, VEGF, FGF) in plasma of patients with psoriasis vulgaris (PsV, n = 20) and psoriatic arthritis (PsA, n = 20) compared to plasma of healthy subjects (control group, n = 20). Mean values ± SD are presented. x statistically significant differences vs. control group, p < 0.05; y statistically significant differences vs. PsA group, p < 0.05.

Figure 5

Figure 5

The level of metalloproteinases (MMP-1, MMP-2, MMP-3, and MMP-7) and metalloproteinase inhibitors (TIMP-1/2) in medium of keratinocytes isolated from psoriatic patents (n = 5) or healthy subjects (n = 5) and cultured following UVB irradiation (60 mJ/cm2) for 24 h with or without cannabidiol (CBD, 4 μM). Mean values ± SD are presented; x statistically significant differences vs. non treated group (control or psoriatic, respectively), p < 0.05; y statistically significant differences between psoriatic and respective-treated control group, p < 0.05; z statistically significant differences between UVB + CBD and only UVB-treated group, p < 0.05.

Figure 6

Figure 6

The level of growing factors and markers of angiogenesis (angiopoietin-2, TNFα, HGF, VEGF, PDGF, FGF) in medium of keratinocytes isolated from psoriatic patents (n = 5) or healthy subjects (n = 5) and cultured following UVB irradiation (60 mJ/cm2) for 24 h with or without cannabidiol (CBD, 4 μM). Mean values ± SD are presented. x statistically significant differences vs. non-treated group (control or psoriatic, respectively), p < 0.05; y statistically significant differences between psoriatic and respective-treated control group, p < 0.05; z statistically significant differences between UVB + CBD and only UVB-treated group, p < 0.05.

References

    1. Michalek I. M., Loring B., John S. M. A systematic review of worldwide epidemiology of psoriasis. J Eur Acad Dermatol Venereol . 2017;31(2):205–212. doi: 10.1111/jdv.13854. – DOI PubMed
    1. Li Q., Chandran V., Tsoi L., et al. Quantifying differences in heritability among psoriatic arthritis (PsA), cutaneous psoriasis (PsC) and psoriasis vulgaris (PsV) Sci. Rep . 2020;10(1):p. 4925. doi: 10.1038/s41598-020-61981-5. – DOI PMC PubMed
    1. Ogawa E., Sato Y., Minagawa A., Okuyama R. Pathogenesis of psoriasis and development of treatment. J. Dermatol . 2018;45(3):264–272. doi: 10.1111/1346-8138.14139. – DOI PubMed
    1. Rendon A., Schäkel K. Psoriasis pathogenesis and treatment. Int. J. Mol. Sci . 2019;20(6):p. 1475. doi: 10.3390/ijms20061475. – DOI PMC PubMed
    1. Ambrożewicz E., Wójcik P., Wroński A., et al. Pathophysiological alterations of redox signaling and endocannabinoid system in granulocytes and plasma of psoriatic patients. Cells . 2018;7:p. 159. doi: 10.3390/cells7100159. – DOI PMC PubMed

Schaka

Related Posts

Dose-Related Inhibition of Capsaicin Responses by Cannabinoids CBG, CBD, THC and their Combination in Cultured Sensory Neurons

Aurora Cannabis Launches Genetics Licensing Business

Aurora Cannabis Launches Genetics Licensing Business

Steep Hill Announces Expansion to Illinois

Thompson Duke Industrial Secures Another Patent for Cannabis Oil Vaporizer Device Filling Equipment

Signez la pétition !!!

 

846 signatures

Pétition ASBL Cannabis Belgique

Pourquoi une pétition ?

Nous sommes des personnes qui en avons assez de devoir aller dans la rue et avoir affaire à des réseaux criminels sans savoir où cela va nous conduire par après.

Nous sommes des personnes ayant des maladies, qui pour certaines sont rares, et utilisant pour médication le cannabis sous diverses formes (CBD,THC,THCv,CBDa,,,) sous l'accord de notre médecin.

Nous sommes des personnes responsables et honnêtes qui avons une vie épanouie et sans problèmes de vie ou sociaux.

Nous avons également une passion pour la plante de cannabis en elle-même et la cultiver est notre bonheur. De plus, nous pouvons nous soigner avec notre médication sans avoir peur des produits ou autres additifs contenus dans une plante que l'on peut trouver autre part.

Nous souhaitons pouvoir avoir notre médicament dans les normes de la santé publique, car un cannabis sain aide à réduire les frais de santé parfois conséquents pour la collectivité et le malade lui-même.

Nous sommes également des personnes responsables avec un rôle dans la société qui en avons assez d’être considérés comme des « hippies ou autres drogués », nous avons juste choisi notre médication et celle-ci a apporté les preuves de son efficacité dans le monde.

Nous connaissons déjà les produits dérivés comme le CBD et le THC que nous maîtrisons pour nous aider dans notre maladie « Je précise que nous ne sommes pas médecin et que nous nous basons sur 20 ans d’expérience médicale du cannabis des membres de notre ASBL et l'avis du médecin de famille ».

Nous désirons simplement ne plus nous cacher, et pouvoir aider les autres personnes le souhaitant.

Nous somme soucieux des ados et de la prévention à leur égard. Effectivement, nous sommes les acteurs parfaits pour répondre aux questions qu’ils se posent vu notre expérience cannabique et, de plus, nous pourrons leur expliquer les risques qu’ils encourent en achetant du cannabis dans la rue.

Le projet complet peut être demandé via mail " info@mcb.care " et sur le site internet : " http://mcb.care "

@ASBL McB

**votre signature**

Partagez avec vos amis

Articles récents

Catégories